Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients
Donald E. Hricik(University Hospitals of Cleveland), Peter S. Heeger(Cedars-Sinai Medical Center), Nancy D. Bridges(National Institute of Allergy and Infectious Diseases), Peter Nickerson(Shared Services Canada), Ian W. Gibson(University of Manitoba), Daniel C. Brennan(Johns Hopkins University), Emilio D. Poggio(Cleveland Clinic), Richard N. Formica(Yale University), Robert L. Fairchild(Cleveland Clinic), Milagros Samaniego(Henry Ford Health System), Helena Diop(National Institutes of Health), Osama Gaber(Methodist Hospital), Kathryn Tinckam(Brigham and Women's Hospital), David Iklé(Rho (United States)), David N. Rush(Manitoba Health), Brian Armstrong(Rho (United States)), Suphamai Bunnapradist(University of California, Los Angeles), Bernd Schröppel(Icahn School of Medicine at Mount Sinai), Chris Wiebe(University of Manitoba)
Cited by 193
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update
|American Journal of Kidney Diseases|2015|1.3k
Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
|American Journal of Transplantation|2003|1.1k